Investment Analysts’ Recent Ratings Changes for Regeneron Pharmaceuticals (REGN)

A number of research firms have changed their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

• 8/17/2026 – Regeneron Pharmaceuticals had its price target raised by Leerink Partners from $641.00 to $824.00. They now have a “market perform” rating on the stock.
• 8/15/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 8/3/2026 – Regeneron Pharmaceuticals had its price target raised by Citigroup Inc. from $700.00 to $740.00. They now have a “neutral” rating on the stock.
• 8/3/2026 – Regeneron Pharmaceuticals had its price target raised by Guggenheim from $1,000.00 to $1,030.00. They now have a “buy” rating on the stock.
• 8/1/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/31/2026 – Regeneron Pharmaceuticals had its price target raised by Royal Bank Of Canada from $696.00 to $737.00. They now have a “sector perform” rating on the stock.
• 7/31/2026 – Regeneron Pharmaceuticals had its price target raised by Morgan Stanley from $730.00 to $758.00. They now have an “equal weight” rating on the stock.
• 7/31/2026 – Regeneron Pharmaceuticals had its price target raised by Cantor Fitzgerald from $750.00 to $795.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Regeneron Pharmaceuticals had its price target raised by Wells Fargo & Company from $700.00 to $750.00. They now have an “equal weight” rating on the stock.
• 7/31/2026 – Regeneron Pharmaceuticals had its price target raised by Truist Financial Corporation from $769.00 to $772.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Regeneron Pharmaceuticals was upgraded by Sanford C. Bernstein to “hold”.
• 7/21/2026 – Regeneron Pharmaceuticals had its price target raised by Guggenheim from $995.00 to $1,000.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Regeneron Pharmaceuticals had its price target lowered by Piper Sandler from $855.00 to $854.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Regeneron Pharmaceuticals had its price target lowered by Morgan Stanley from $788.00 to $730.00. They now have an “equal weight” rating on the stock.
• 7/7/2026 – Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $707.00 to $696.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Regeneron Pharmaceuticals was upgraded by Benchmark Co. from “hold” to “buy”. They now have a $185.00 price target on the stock.
• 7/7/2026 – Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation from $778.00 to $769.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Regeneron Pharmaceuticals had its price target lowered by HSBC Holdings plc from $990.00 to $880.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Regeneron Pharmaceuticals had its price target lowered by Cantor Fitzgerald from $785.00 to $750.00. They now have an “overweight” rating on the stock.
• 7/4/2026 – Regeneron Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/24/2026 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,400 shares of company stock worth $1,090,030. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.